A

Aurinia Pharmaceuticals
D

AUPH

8.85000
USD
0.09
(0.97%)
Market Closed
Volume
60,058
EPS
0
Div Yield
-
P/E
-59
Market Cap
1,267,136,531
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    D
    DVAX
    -1.180
    (-8.81%)
    12.210 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    L
    LGND
    -3.790
    (-3.28%)
    111.690 USD
    R
    RARE
    -2.865
    (-6.02%)
    44.745 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: Aurinia Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.